<DOC>
	<DOCNO>NCT02807116</DOCNO>
	<brief_summary>The primary objective evaluate effect rifampin , potent cytochrome P450 3A4 inducer , steady-state systemic exposure single dose pacritinib healthy subject .</brief_summary>
	<brief_title>Drug-Interaction Study Evaluate Effect Rifampin , Potent CYP3A4 Inducer , Systemic Exposure Pacritinib Healthy Subjects</brief_title>
	<detailed_description>This single-center , open-label , one-way crossover , drug-interaction study . On Day 1 , subject receive single oral 400-mg dose pacritinib . Following 7-day washout period , 600-mg oral dos rifampin administer daily ( QD ) Days 8 17 . It anticipate steady-state concentration rifampin would achieve Day 17 . On Day 17 , single oral 400-mg dose pacritinib co-administered final 600-mg dose rifampin .</detailed_description>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Cytochrome P-450 CYP3A Inducers</mesh_term>
	<criteria>Subjects meet follow criterion may include study : 1. male female , 18 55 year age , inclusive ; 2 . BMI 18.5 32.0 kg/m2 , inclusive ; 3. good health , determine clinically significant finding medical history , physical examination , vital sign measurement ; 4. clinical laboratory evaluation ( include clinical chemistry panel [ fast least 10 hour ] , CBC , UA ) within reference range test laboratory , unless deem clinically significant Investigator consultation Sponsor ; 5. negative test select drug abuse ( include alcohol ) Screening Checkin ( Day 1 ) ; 6. negative hepatitis panel ( include hepatitis B surface antigen [ HBsAg ] hepatitis C virus antibody [ antiHCV ] ) negative HIV antibody screen ; 7. female childbearing potential must nonpregnant nonlactating , agree use one follow form contraception time sign Informed Consent Form ( ICF ) 10 day prior Checkin ( Day 1 ) 30 day final dose administration : nonhormonal intrauterine device ( IUD ) spermicide ; female condom spermicide ; contraceptive sponge spermicide ; intravaginal system ( eg , NuvaRing® ) ; diaphragm spermicide ; cervical cap spermicide ; male sexual partner agree use male condom spermicide ; sterile sexual partner ; abstinence . Oral , implantable , transdermal , injectable hormonal contraceptive may use time sign ICF 10 day prior Checkin ( Day 1 ) 14 day final dose administration . For female , pregnancy test result must negative Screening Checkin ( Day 1 ) . Females childbearing potential must continuous amenorrhea least 12 month surgically sterile ( eg , tubal ligation , hysterectomy ) least 90 day prior Screening ; 8. male either surgically sterile ( ie , vasectomy , document medical record physician ) agree use , Checkin ( Day 1 ) 90 day follow Study Completion/Early Termination ( ET ) , one follow approve method contraception : male condom spermicide ; sterile sexual partner ; use female sexual partner IUD spermicide ; female condom spermicide ; contraceptive sponge spermicide ; intravaginal system ; diaphragm spermicide ; cervical cap spermicide ; oral , implantable , transdermal , injectable contraceptive . Subjects must agree refrain sperm donation Checkin ( Day 1 ) 90 day follow Study Completion/ET ; 9. able comprehend willing sign ICF The following exclude potential subject study : 1. history clinical manifestation clinically significant cardiovascular , pulmonary , hepatic ( eg , hepatitis ) , renal , hematologic , gastrointestinal ( eg , celiac disease , peptic ulcer , gastroesophageal reflux , inflammatory bowel disease ) , metabolic , allergic , dermatological , neurological , psychiatric disorder ( determined Investigator ; appendectomy cholecystectomy consider clinically significant procedure ) ; 2. abnormality liver function test ( any/all alanine aminotransferase , aspartate aminotransferase , alkaline phosphatase &gt; upper limit normal [ ULN ] ; gammaglutamyl transferase &gt; ULN ; total bilirubin &gt; ULN ) kidney function test ( serum creatinine &gt; ULN ) ; laboratory value may confirm repeat ; 3. history malignancy , except follow : cancer determine cured remission ≥5 year , curatively resect basal cell squamous cell skin cancer , cervical cancer situ , resect colonic polyp ; 4. history significant hypersensitivity , intolerance , allergy drug compound , food , substance , include rifampin , unless approve Investigator consultation Sponsor ; 5. history stomach intestinal surgery resection would potentially alter absorption and/or excretion orally administer drug except appendectomy hernia repair allow ; 6. history Gilbert 's Syndrome ; 7. history presence abnormal ECG , , Investigator 's opinion , clinically significant ; QT correct heart rate use Fridericia 's formula ( QTcF ) &gt; 450 msec ; factor increase risk QTc interval prolongation ( eg , heart failure , hypokalemia [ define serum potassium &lt; 3.0 mEq/L persistent refractory correction ] , family history long QT interval syndrome ) ; 8. history alcoholism drug addiction within 1 year prior Checkin ( Day 1 ) ; 9. use tobacco nicotinecontaining product within 6 month prior Checkin ( Day 1 ) entire study ; 10. receipt blood product within 2 month prior Checkin ( Day 1 ) ; 11. participation investigational drug trial receipt investigational study drug occur within 5 halflives 30 day prior Checkin ( Day 1 ) , whichever longer ; 12. donation blood 30 day prior Screening Study Completion/ET , inclusive , plasma 2 week prior Screening Study Completion/ET , inclusive ; 13. use prescription medication and/or product within 14 day prior Checkin ( Day 1 ) entire study , unless deem acceptable Investigator consultation Sponsor ; 14. use oral , implantable , injectable , transdermal hormonal contraceptive within 10 day prior Checkin ( Day 1 ) time sign ICF ( female ) 14 day final dose administration ; 15. use overthecounter , nonprescription preparation ( include vitamin , mineral , phytotherapeutic/herbal/plantderived preparation ) within 7 day prior Checkin ( Day 1 ) entire study , unless deem acceptable Investigator ; 16. consumption alcohol caffeinecontaining food beverages 72 hour prior Checkin ( Day 1 ) entire study ; 17. consumption grapefruitcontaining food beverage CYP3A4 inhibitor inducers 72 hour prior Checkin ( Day 1 ) entire study ; 18. participation strenuous exercise 48 hour prior Checkin ( Day 1 ) period confinement CRU ; subject otherwise maintain normal level physical activity throughout entire study ( ie , begin new exercise program participate unusually strenuous physical exertion ) ; 19. poor peripheral venous access ; 20. acute chronic condition , opinion Investigator , would limit subject 's ability complete and/or participate clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Drug-Interaction Study</keyword>
</DOC>